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Abstract
Pharmaceuticals and personal care products (PPCPs) encompass a large class of chemical 
contaminants that can originate from human usage and excretions and veterinary appli-
cations. These pollutants have captured the attention of scientists, governments, and the 
public as several studies across the globe reveal their widespread occurrence in low-
level concentrations in wastewater and the aquatic environment. Most of the research on 
PPCPs has been generated from efforts in highly developed countries, primarily North 
America and Europe, although investigations and reports are emerging from Southeast 
Asia and China. With the increased concern of potential threats triggered by the occur-
rence of these chemicals in the environment, environmental risk assessment (ERA) strate-
gies for such compounds have considerably evolved over the past decade. Regulations 
are in effect or planned in several western nations, however, there is no global standard 
for conducting ERAs. As the scope of the problem evolves, substantial research will be 
imperative to address these contaminants and their occurrence in the environment. This 
chapter will discuss the evolution of the risk associated with the occurrence of PPCPs in 
the environment, the challenges faced by their existence here, and the colloquy about 
solutions to address this escalating issue.
Keywords: pharmaceuticals and personal care products (PPCPs), pharmaceuticals, 
contaminants of emerging concern (CECs), environmental risk assessment (ERA), 
aquatic environment
1. Introduction
Anthropogenic pollutants enter surface and ground waters via a multitude of processes. 
Commercial activities such as manufacturing emissions, waste disposal, and accidental 
releases are a few examples [1]. Other practices include deliberate introduction such as 
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sewage sludge application to land, groundwater recharge, and consumer activity which 
involves both the excretion and purposeful disposal of a wide range of naturally occurring 
and anthropogenic chemicals [1, 2]. During the last few decades, the impact of chemical pol-
lution in the water has focused almost exclusively on the conventional “priority pollutants” 
[3]. Priority pollutants are a group of chemicals regulated under legislation such as the Clean 
Water Act (CWA) of 1972 by the United States Environmental Protection Agency (US EPA) and 
the Water Framework Directive (2000/60/EC) (WFD), an updated version of Council Directive 
76/464/EEC, by the Environment Directorate General of the European Commission (DG 
Environment) for the European Union (EU) [4, 5]. These pollutants are chemicals that have 
specific effects on organisms, comprised mainly of agricultural and industrial chemicals and 
their synthesis by-products [4–6]. The prioritized lists of 126 pollutants and 33 substances in 
the US and EU, respectively, currently include chemicals that were selected primarily because 
of their toxicity, persistence, and degradability, among other factors [4, 7, 8]. Chemical pro-
duction rates and the frequency of occurrence in waters was also considered [4, 5].
Pharmaceuticals and personal care products (PPCPs) are among a group of chemicals termed 
“contaminants of emerging concern” (CECs). CECs are not necessarily new pollutants as 
they may have been present in the environment for several years, but their presence and sig-
nificance are only now being evaluated [3]. Due to their medical properties, PPCPs have an 
inherent biological effect; furthermore, they behave as persistent pollutants because of their 
continual infusion into the aquatic ecosystem [9–11].
2. Risks
Considering scientific literature dating as far back as the early 1900s, more than 130 million 
organic and inorganic substances had been indexed by the American Chemical Society in the 
Chemical Abstracts Service (CAS) Registry, which is updated daily with about 15 thousand 
new substances [12]. Over eight million chemicals are commercially available, but only 350 
thousand are inventoried and/or regulated globally [4, 8, 12–14].
Figure 1 shows that the majority of chemicals in commerce are “industrial” chemicals, a sig-
nificant percentage of these chemicals fall into the categories of “cosmetics ingredients” and 
“pharmaceuticals”. Collectively, these two categories contain several compounds that are 
potentially persistent and bioaccumulative [14]. Caffeine, nicotine, and aspirin are a few of 
the pharmaceutically active compounds that have been known for years to enter the environ-
ment [3]. Only more recently has it become evident that drugs and personal care products 
from a wide spectrum of therapeutic and consumer-use classes exist in the environment in 
low concentrations [15, 16]. Over 50 million pounds of antibiotics are produced annually in 
the United States, with approximately 60% for human use and 40% for animal agriculture, 
therefore, veterinary medicines contribute considerably to PPCP occurrence [17]. In addition 
to pharmaceuticals, compounds such as synthetic fragrances, detergents, disinfectants, and 
insect repellents are among the man-made chemicals that are now beginning to accumulate 
in the natural environment [18].
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Increasing introduction to the marketplace of new pharmaceuticals is adding to the already 
large array of poorly understood chemical classes that each have distinct modes of biochemi-
cal action [1]. In the United States, legislation exists that requires an assessment of potential 
risk to the environment by new pharmaceutical products. Under this policy, the Food and 
Drug Administration (US FDA) is required to consider the environmental impacts of manu-
facture, use, and distribution of human drugs as well as investigational use and approvals 
of veterinary drugs [19, 20]. The European Commission recently published a Roadmap that 
acknowledges the Commission’s effort toward developing a similar strategy that will address 
the manufacture, use and disposal of active pharmaceutical ingredients [21].
Figure 2 illustrates the numerous pathways by which antibiotics and other PPCPs are intro-
duced into the environment which can be both point and non-point sources [22, 23]. Municipal 
sewage, both treated and untreated, is the most likely route for human use drugs to enter the 
environment. Wastewater treatment processes achieve variable and often incomplete removal 
of antibiotics [24, 25]. Human pharmaceuticals are excreted from the body in urine and feces 
as unchanged parent compounds, metabolites or conjugated substances; furthermore, because 
of their polarity, water solubility and persistence some of these compounds may not be com-
pletely eliminated or transformed during sewage treatment [26, 27]. Therefore, residential 
and commercial healthcare facilities, specifically hospitals, are known contributors of antibi-
otics to municipal wastewater [2, 19, 28–30]. Additionally, the incorrect disposal of expired 
or unwanted medicines in the sink, toilet, or in household solid waste that is then taken to 
landfills contribute to the occurrence of pharmaceuticals in wastewater [31–33]. Another pos-
sible pathway begins with the disposal of unwanted illicit drugs, synthesis byproducts, raw 
products and intermediates into domestic sewage systems by clandestine drug operations 
[3, 32, 34]. Other probable entries include leakage from pipelines, tanks, waste ponds or land-
fills, and atmospheric deposition [35].
Figure 1. Estimated number and categories of chemicals in commerce registered for use in the United States over the past 
30 years. Not all chemicals may be in current use. Similar proportions would be anticipated in other countries. Adapted 
with permission from [14]. Copyright 2006 American Chemical Society.
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Veterinary medicines may enter the environment through a number of pathways, with ter-
restrial runoff from concentrated animal feeding operations (CAFOs) and wind-borne drift 
of agriculturally-applied antimicrobials to crops being the primary sources [32, 34, 36]. After 
administration, the substances may be metabolized in the animal which changes their physi-
cal, chemical and eco-toxicological properties, but even metabolites may be reconverted to 
their parent compounds after excretion [37, 38]. Accidental leakage or leaching from animal 
waste storage can also be a source. Still another major channel by which veterinary antibiotics 
are released into the environment is through application of manure or slurry to agricultural 
fields as fertilizer [34, 36, 39].
Dependent upon the chemical properties and structures of PPCPs, several processes can affect 
the fate and transport of these compounds in the environment. These include, but are not 
limited to, sorption, biotic transformation, and abiotic transformation [7, 24, 27]. Most PPCPs 
are water soluble and have a low volatility, although there are few that may strongly adsorb 
to soils and are somewhat persistent. These characteristics allow them to be easily transported 
and omnipresent in various aquatic environments [7, 19]. Because PPCPs can be introduced 
on a continual basis to the aquatic environment, they are ubiquitously present in waters; their 
removal or transformation by biodegradation, hydrolysis, photolysis, and other processes is 
continually countered by their replenishment [3].
Figure 2. Source, fate, and distribution of PPCPs in the environment.
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With concentrations typically ranging from the low parts per trillion (ppt) and parts per bil-
lion (ppb) levels, several individual PPCPs or their metabolites from a variety of therapeu-
tic classes (Table 1) have been detected in environmental samples from all over the world 
[3]. More than 80 pharmaceuticals and their metabolites have been detected in almost 
Therapeutic class Examples of generic names Examples of brand names
Analgesics/non-steroidal anti-inflammatories (NSAIDs) Acetaminophen (analgesic)
Diclofenac
Ibuprofen
Ketoprofen
Naproxen
Tylenol
Voltaren
Advil
Oruvail
Naprosyn
Antimicrobials/antibiotics e.g., sulfonamides, 
fluoroquinolones
Many
Antiepileptics Carbamazepine Tegretal
Antihypertensives (betablockers, beta-adrenergic 
receptor inhibitors)
Bisoprolol
Metoprolol
Concor
Lopressor
Antineoplastic Cyclophosphamide
Ifosfamide
Cycloblastin
Holoxan
Antiseptics Triclosan Irgasan DP 300
Contraceptives β-Estradiol
17a-Ethinyl estradiol
Diogyn
Oradiol
Hormonally active agents
Androgens
Anti-acne agents adrenocorticosteroids inhalable Steroids
Estrogen antagonists
Fluoxymesterone
Isotretinoin
Tretinoin
Prednisone
Triamcinolone
Fluticasone
Tamoxifen
Accutane
Retin-A
Flovent
Nolvadex
β
2
-Sympathomimetics (bronchodilators) Albuterol Ventolin
Lipid regulators (anti-lipidemics; cholesterol-reducing 
agents; and their bioactive metabolites)
Clofibrate (active metabolite: 
clofibric acid)
Gemfibrozil
Atromid-S
Lopoid
Musks (synthetic) Nitromusks
Polycyclic musks
Reduced metabolites of 
nitromusks
Musk xylene
Celestolide
Substituted amino 
nitrobenzenes
Anti-anxiety/hypnotic agents Diazepam Valium
Sun screen agents Methylbenzylidene camphor 
avobenzene
Octyl methoxycinnamate
Eusolex 6300
Parsol A
Parsol MOX
X-ray contrast agents Diatrizoate Hypaque
Adapted with permission from [3]. Copyright 2001 American Chemical Society.
Table 1. Chemical classes (and members) of PPCPs detected in environmental samples.
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Chemical class Location Concentration range (ng/L) References
Multiple pharmaceuticals North America
U.S.
ND – 72 [51]
East Asia
China
Japan
Korea
ND – 5911 [52–57]
Europe
Finland
Norway
Portugal
U.K.
ND – 126,000 [58–61]
Antimicrobials/antibiotics North America
U.S.
90–320 [24, 62]
East Asia
China
Korea
ND – 21,278 [52, 63–72]
Europe
Finland
Sweden
U.K.
ND – 3052 [61, 73, 74]
Hormonally active agents North America
Canada
0.2–96 [75]
East Asia
China
Japan
Korea
ND – 253.8 [52, 53, 
76–83]
Europe
Portugal
ND – 25 [60]
Antiepileptics East Asia
China
230–1110 [84]
Antiseptics Europe
Norway
160–480 [59]
Musks (synthetic) North America
U.S.
495–3730 [85]
East Asia
China
Japan
<4–2050 [86–89]
Europe
Portugal
1–889 [60]
Sun screen agents East Asia
China
21–1287 [90]
Europe
U.K.
<2–6325 [61]
ND: not detected.
Table 2. Representation of the global occurrence of PPCPs in WWTP effluents.
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every aquatic environment in North America and Europe surface waters [33, 40–44]. A 
national reconnaissance study on the occurrence of pharmaceuticals, hormones, and other 
organic wastewater contaminants (OWCs) in United States streams found that one or more 
OWCs were found in 80% of the stream samples, with 82 compounds of the 95 analyzed for 
detected during the study [40]. In another project, source water, finished drinking water, 
and distribution system (tap) water from 19 United States drinking-water treatment (DWT) 
plants was analyzed for 51 pharmaceuticals and pharmaceutical metabolites. Targeted 
compounds were detected most frequently in source water with at least one compound 
being detected in all 19 source waters; they were also found in approximately 89% of fin-
ished drinking waters and 87% of distribution systems [45]. In yet another study conducted 
by the United States Geological Survey (USGS) and the Centers for Disease Control and 
Prevention (CDC), several compounds that were frequently detected in samples of stream 
water and raw-water supplies were also detected in samples collected throughout the DWT 
facility, indicating that these compounds resist removal through conventional water-treat-
ment processes [46].
PPCPS have been reported in hospital wastewaters, wastewater treatment plant (WWTP) 
effluents, WWTP biosolids, soil, surface waters, groundwaters, sediments, biota, and drink-
ing water [33, 40, 47–50]. Since WWTPs are considered a major source of these pollutants, 
several investigations of environmental loads of PPCPs examine WWTP effluents (Table 2) 
[28]. There is less documented research of PPCP occurrence in coastal or marine ecosystems. 
A wide distribution of clofibric acid, caffeine, and DEET in concentrations up to 19, 16, and 
1.1 ng/L, respectively, was measured throughout the North Sea and along European coasts 
[91]. Sulfamethoxazole, carbamazepine, tamoxifen, and indomethacin were discovered in 
China in the Yangtze River Estuary at levels ranging from 4.2 to 159 ng/L [92]. In the United 
States, sulfamethoxazole was detected in at least four bays ranging in concentrations from 
4.8 to 65 ng/L, while trimethoprim was found at a maximum concentration of 72.2 ng/L in 
Jamaica Bay, New York and 2.1 ng/L off the coast of California [93–95].
3. Challenges
An ecological or environmental risk assessment (ERA) is defined as the means of evaluating 
the probabilities and magnitudes of adverse effects to human health or ecological receptors, 
directly or indirectly, as a result of exposure to pollutants and other anthropogenic activities 
[96]. ERAs are employed to estimate any potential harm that could emerge from environ-
mental contaminants, with a known degree of certainty, using scientific methodologies. The 
innovation of ERAs has become necessary as improved research reveals chemicals in the envi-
ronment at levels that are potentially toxic to humans and/or our valuable natural resources 
[11]. The specific methodology for carrying out an ERA may vary depending on the chemical 
being assessed, but the core principles and the key stages of the process are fundamentally 
the same in each case (Figure 3).
ERAs can be used to predict the likelihood of future adverse effects, prospective, or to evalu-
ate the likelihood that effects are caused by past exposure to stressors, retrospective [97]. 
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Examples of prospective uses include establishing drinking water goals or wastewater 
discharge limits. Federal and state regulatory programs also utilize prospective ERAs to 
reduce toxic tort liabilities and improved public relations. The government may use retro-
spective ERAs as a decision making tool, for example, when determining Comprehensive 
Environmental Response, Compensation, and Liability Act – CERCLA or Superfund – proj-
ects [11, 98, 99]. In many cases, both approaches are included in a single risk assessment. 
Combined retrospective and prospective risk assessments tend to be beneficial in situations 
where ecosystems have a history of previous impacts and/or the potential for future effects 
from multiple chemical, physical, or biological stressors [97].
Although the concentrations of these PPCPs generally range from the low ppt- to ppb-lev-
els, there is increasing evidence that PPCPs may have significant impacts on natural biotic 
communities. There are two major concerns with the presence of low-level concentrations 
of pharmaceuticals in the aquatic environment: the potential toxicity of these compounds 
to aquatic organisms and the exposure to humans through drinking water [23, 31, 100]. 
Some PPCPs, such as antidepressants, birth control drugs, and other medications have been 
detected in fish tissue and were identified as the cause of neurological, biochemical, and 
physiological changes [100, 101]. Because pharmaceuticals are designed to target specific 
metabolic and molecular pathways in humans and animals, it is assumed that they may 
affect the same pathways in animals with identical or similar target organs, tissues, cells 
or biomolecules. Certain receptors in lower vertebrates resemble those in humans, while 
others are different or lacking; in these cases, dissimilar modes of actions may occur in the 
lower animals [102, 103].
Figure 3. Flow chart for a general ERA process.
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Acute toxicity studies typically show that the concentrations of PPCPs to produce effects such 
as death in half of the exposed organisms (EC50) range of 25 to ≥500 mg/L; one particular 
example found that the chronic toxicity or median lethal dose (LC50) of furazolidone, which is largely used in medicated fish feed, at 40 mg/kg in the mosquito larvae, Culex pipiens [31]. 
In a study that tested the effects of tylosin and oxytetracycline on three species of soil fauna, 
neither of the substances had any effect at environmentally relevant concentrations; however, 
as soil ecosystems are built up by complex and linked food webs, the study concluded that it 
is not yet possible to exclude that indirect effects on soil fauna driven by changes in the micro-
bial community and alteration of the decomposer system may occur [38].
Since antibiotics are specifically designed to control bacteria in plants and animals of eco-
nomic interest, this obviously makes them hazardous to bacteria and other micro-organisms 
in the environment. There is growing concern that low level concentrations of antibiotics in 
the environment contribute to the emergence of strains of disease-causing bacteria that are 
resistant to even high doses of these drugs [23]. Current evidence supports that feeding low 
doses of antibiotics to livestock in an attempt to improve production efficiency has produced 
resistant strains of certain microorganisms. Bacterial strains evolve and become resistant to 
multiple antibiotics if they are continually exposed to low doses of antibiotics in the environ-
ment since the three mechanisms of gene transfer – conjugation, transduction, and transfor-
mation – all occur in the aquatic environment [104].
Streams and rivers that receive low levels of chronic antibiotic exposure can be viewed as a 
source and a reservoir of resistant genes as well as a means for their dispersion. In addition, 
if non-target organisms, such as cyanobacteria, are over-exposed to antibiotics, they may be 
negatively affected, which will disturb the aquatic food chain [6]. Increased bacterial resis-
tance has been seen in waste effluent from hospitals and pharmaceutical plants indicating that 
the ultimate disposal of antibiotics may be a serious public health issue [23, 29]. Furthermore, 
individual compounds may interact synergistically or antagonistically with other chemicals 
present in the environment [6, 15, 16].
4. Solutions
The production and usage of most pharmaceutical and personal care products will either sta-
bilize or increase. It is probable that the environmental load of these chemicals will follow the 
same trend. Although remedying this issue seems unfeasible, it cannot be regarded as a terminal 
quandary. Instead, tactics should be implemented to minimize their impact on the environment.
There are four major factors that determine the concentrations of drug residues reported in 
environmental samples: (1) frequency of use, (2) excretion of un-metabolized drugs, (3) per-
sistence on biodegradation, and (4) the analytical method used [105]. Due to the consequential 
concern resulting from the detection of PPCPs in the aquatic environment, sensitive analytical 
techniques have been developed to investigate this new class of environmental pollutants; tech-
niques that will have to continue to evolve in order to improve method accuracy and sensitivity 
[105]. Likewise, methodology must be designed to analyze compounds in combination [93].
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Perhaps reform should begin with production of PPCPs, specifically pharmaceuticals. 
Medicinal drugs are intended to be metabolized by organisms, yet, approximately 20% or 
more of these compounds are excreted in their parent form or as metabolites [26, 105]. After 
excretion, these compounds could possibly mix with other chemicals already present in the 
environment or biodegradation and transformation may occur: circumstances which could 
produce other metabolites or by-products, conceivably leading to a substance that may be 
far more toxic than the parent compounds [105]. Production of pharmaceuticals that are fully 
absorbed or completely metabolized by the organism would be ideal; this, however, may be 
impractical. The responsibility then shifts from the pharmaceutical industry to the medical 
industry. By purposefully managing prescriptions with deep scrutiny, doctors may begin to 
begin to alleviate the issue through reduction of input [26].
Effective regulation of PPCPs is implausible without a global colloquy giving great consider-
ation to the creation and installation of a well-developed, universal ERA procedure for these 
contaminants. Existing protocols must be expanded to adapt to the gravity of the potential 
impacts of these unique compounds in the environment. Implementation of a retrospective 
aspect to the protocol may also be necessary in the near future [93].
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